Novo Nordisk A/S-B is banking on high demand for its new weight-loss pill to counter a deepening price war with Eli Lilly & Co. The Denmark-based drugmaker faces pressure to prove that rising prescription volumes can offset falling margins in the obesity market. Investors are looking for a shift from defensive to offensive strategy after a $400B market value decline since a 2024 peak.

Volume Growth vs. Pricing Pressure